心脏结节病激素治疗前后FDG PET代谢体积测量的适宜参考组织探讨
该研究回顾性纳入38例心脏结节病患者,比较激素治疗前后肝脏与降主动脉的FDG摄取变化。结果显示激素治疗期间肝脏SUVmax、SUVmean、SUVpeak显著升高,而降主动脉各参数无显著变化。提示降主动脉摄取较肝脏更适合作为体积分析评价疗效的阈值参考。
要点
- 激素治疗期间肝脏SUVmax、SUVmean、SUVpeak较治疗前显著升高。
- 降主动脉SUVmax、SUVmean、SUVpeak在激素治疗前后无显著变化。
- 降主动脉摄取可能较肝脏更适合作为CMV分析的阈值参考。
核心结论
- 激素治疗升高肝脏FDG摄取但不改变血池(降主动脉)摄取,提示降主动脉摄取较肝脏更适合作为心脏FDG PET体积分析评价疗效的阈值。
研究设计与样本
- 回顾性纳入38例心脏结节病患者,在激素治疗前及治疗期间行FDG PET/CT,比较肝脏右叶与降主动脉感兴趣区的SUVmax、SUVmean、SUVpeak。
主要发现
- 肝脏SUVmax治疗前3.5 ± 0.4 vs 治疗期间3.8 ± 0.6(升高,p = 0.014)。
- 肝脏SUVmean治疗前2.7 ± 0.3 vs 治疗期间3.0 ± 0.5(升高,p = 0.0065)。
- 肝脏SUVpeak治疗前3.0 ± 0.4 vs 治疗期间3.4 ± 0.6(升高,p = 0.006)。
- 降主动脉SUVmax治疗前2.2 ± 0.3 vs 治疗期间2.2 ± 0.4(无显著变化,p = 0.46)。
- 降主动脉SUVmean治疗前1.9 ± 0.3 vs 治疗期间2.0 ± 0.4(无显著变化,p = 0.56);SUVpeak治疗前2.0 ± 0.3 vs 治疗期间2.0 ± 0.3(无显著变化,p = 0.70)。
临床怎么用
- 在激素治疗前后采用体积分析评价心脏FDG PET疗效时,降主动脉摄取较肝脏摄取更适合作为阈值参考。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac sarcoidosis (CS) is a rare but potentially life-threatening disease that causes conduction disturbance, systolic dysfunction, and, most notably, sudden cardiac death. 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays important roles not only in diagnosing CS but also in evaluating the effects of anti-inflammatory therapy. A volume-based analysis of parameters measured by FDG PET, so-called cardiac metabolic volume (CMV), has emerged as a new assessment tool. CMV is measured as the volume within the boundary determined by a reference tissue such as the liver and the blood pool uptake. However, there is a possibility that oral steroid therapy could lead to variations of the liver and the blood pool uptake. Here, we attempted to evaluate the steroid effects on the liver and the blood pool uptake. A total of 38 CS patients who underwent FDG PET/CT before and during steroid therapy were retrospectively enrolled. Volumes of interest (VOIs) were placed in the right lobe of the liver and descending aorta (DA). The maximum standardized uptake value (SUVmax), SUVmean, and SUVpeak of the liver and DA were compared between time points before and during steroid therapy. RESULTS: The SUVmax, SUVmean, and SUVpeak of the liver during steroid therapy significantly increased from the time point before the therapy (SUVmax 3.5 ± 0.4 vs. 3.8 ± 0.6, p = 0.014; SUVmean 2.7 ± 0.3 vs. 3.0 ± 0.5, p = 0.0065; SUVpeak 3.0 ± 0.4 vs. 3.4 ± 0.6, p = 0.006). However, the SUVmax, SUVmean, and SUVpeak in the DA did not significantly change (SUVmax 2.2 ± 0.3 vs. 2.2 ± 0.4, p = 0.46; SUVmean 1.9 ± 0.3 vs. 2.0 ± 0.4, p = 0.56; SUVpeak 2.0 ± 0.3 vs. 2.0 ± 0.3, p = 0.70). CONCLUSIONS: We measured FDG uptake in the liver and blood pool before and during steroid therapy. Steroid therapy increased the liver uptake but not the blood pool uptake. Our findings suggested that the DA uptake is a more suitable threshold than liver uptake to evaluate therapeutic effects using volume-based analysis of cardiac FDG PET.
引用
- Furuya S, Manabe O, Ohira H, et al. Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy? EJNMMI Res. 2018. PMID: 30291527. doi:10.1186/s13550-018-0447-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。